Washington has bought the global stock of this Covid-19 treatment. L’Express takes stock of what we know about its effectiveness.
Countries seeking to procure remdesivir will have to wait. The Trump administration will acquire almost all of the global stock of this treatment against Covid-19. According to the US Department of Public Health, the United States and the pharmaceutical company Gilead have agreed to acquire 500,000 doses, or all of the production for the month of July and 90% of the months of August and September.
Remdesivir is the first drug approved by US health authorities to treat Covid-19. For its part, the European Medicines Agency (EMA) recommended last Thursday the authorization of a “conditional marketing” of the antiviral within the EU for serious patients with the new coronavirus. This authorization must now be approved or not by the European Commission “in the coming week”. Here is what we know about the effectiveness of this treatment.
Article reserved for subscribers
To continue reading, subscribe and take advantage of our SPECIAL SUMMER OFFER
2 months for 1 €
I subscribe now
Included in the Digital and Audio subscription
- Audio magazine and augmented digital magazine
- Masterclass of The Express
- Unlimited access to ad-free articles
- Access to all newsletters
Already subscribed? To log in